AN INDIRECT TREATMENT COMPARISON (ITC) OF IFINATAMAB DERUXTECAN (I-DXD) VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY (RWPCT) IN PATIENTS PREVIOUSLY TREATED WITH AT LEAST 2 LINES OF THERAPY (LOTS) FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER...
Author(s)
Jie Meng, MIHMEP1, Jingjing Yin, PhD1, Françoise Diamand, MSc2, Maha Karnoub, PhD1, Sajid Ahmed, PharmD1, Carsyn Norway, PharmD1, Kamya Sankar, MD3;
1Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 2Daiichi Sankyo France SAS, Rueil-Malmaison, France, 3Cedars-Sinai Medical Center, Samuel Oschin Cancer Center, Los Angeles, CA, USA
1Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 2Daiichi Sankyo France SAS, Rueil-Malmaison, France, 3Cedars-Sinai Medical Center, Samuel Oschin Cancer Center, Los Angeles, CA, USA
OBJECTIVES: Patients with ES-SCLC experience rapid disease progression and have limited treatment options and poor outcomes. The B7-H3-directed antibody-drug conjugate I-DXd demonstrated promising efficacy in patients with previously treated ES-SCLC in the Phase 2 IDeate-Lung01 study (NCT05280470). Given the lack of a comparator arm in IDeate-Lung01, an ITC was conducted to contextualize the results to current standard therapies using real-world data collected for a US Flatiron Health database analysis (Sankar et al, ISPOR 2025, abstract RWD155), to help inform the future role of I-DXd in managing patients with previously treated ES-SCLC.
METHODS: The I-DXd cohort (n=105) included adults who received I-DXd 12 mg/kg as third- or fourth-line treatment in IDeate-Lung01 (data cutoff: March 3, 2025). The real-world cohort (n=297) included adults with ES-SCLC who initiated first-line rwPCT in/after January 2018 and received third-line or fourth-line rwPCT (chemotherapy [including lurbinectedin], anti-PD-[L]1, or chemotherapy + anti-PD-[L]1) in/before June 2023. Matching-adjusted indirect comparison methodology was used to weight patients in the I-DXd cohort to adjust for differences in key prognostic factors and treatment-effect modifiers between cohorts. Overall survival (OS), progression-free survival (PFS), and time to treatment discontinuation (TTD) were compared.
RESULTS: In the real-world cohort, mean age was 65.1 years; 75.8% of patients had received 2 prior LOTs, and 24.2% had received 3 prior LOTs; patient characteristics were similar in the weighted I-DXd cohort (effective sample size, 68.5). PFS and OS were significantly longer with I-DXd than with rwPCT: median (95% CI) PFS was 4.3 (3.2-5.4) versus 2.8 (2.5-3.1) months, and median (95% CI) OS was 10.4 (9.4-14.0) versus 6.1 (5.1-6.8) months. Results for TTD were consistent with PFS.
CONCLUSIONS: I-DXd demonstrated longer OS, PFS, and TTD than rwPCT in this ITC, supporting its potential as a promising treatment option for patients with previously treated ES-SCLC.
METHODS: The I-DXd cohort (n=105) included adults who received I-DXd 12 mg/kg as third- or fourth-line treatment in IDeate-Lung01 (data cutoff: March 3, 2025). The real-world cohort (n=297) included adults with ES-SCLC who initiated first-line rwPCT in/after January 2018 and received third-line or fourth-line rwPCT (chemotherapy [including lurbinectedin], anti-PD-[L]1, or chemotherapy + anti-PD-[L]1) in/before June 2023. Matching-adjusted indirect comparison methodology was used to weight patients in the I-DXd cohort to adjust for differences in key prognostic factors and treatment-effect modifiers between cohorts. Overall survival (OS), progression-free survival (PFS), and time to treatment discontinuation (TTD) were compared.
RESULTS: In the real-world cohort, mean age was 65.1 years; 75.8% of patients had received 2 prior LOTs, and 24.2% had received 3 prior LOTs; patient characteristics were similar in the weighted I-DXd cohort (effective sample size, 68.5). PFS and OS were significantly longer with I-DXd than with rwPCT: median (95% CI) PFS was 4.3 (3.2-5.4) versus 2.8 (2.5-3.1) months, and median (95% CI) OS was 10.4 (9.4-14.0) versus 6.1 (5.1-6.8) months. Results for TTD were consistent with PFS.
CONCLUSIONS: I-DXd demonstrated longer OS, PFS, and TTD than rwPCT in this ITC, supporting its potential as a promising treatment option for patients with previously treated ES-SCLC.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD122
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology